CardioVoyage, LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$38,252	30
2024	Research	$55,777	59
2022	Research	$34,945	1
2021	Research	$666,417	1
2020	Research	$29,168	1
2019	Research	$77	1

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $730,608 4 payments
Dompe Farmaceutici S.p.A. $79,199 87 payments
Cleerly, Inc. $14,830 2 payments

Studies the money was for Research payments · program years 2019–2025

AMG 407 (OTEZLA) - Ph 3 COVID Consortium Study $701,362 2 payments
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinational, multicentre, randomised, double-blinded, placebo-controlled, parallel-group phase III trial. (REPAVID-22) $55,888 68 payments
Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory Distress Syndrome (RESPIRATIO) $23,311 19 payments
Paramount $14,830 2 payments
Galactic-Hf $77 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.